Back to announcement
20231122_KLBF_Laporan Informasi dan Fakta Material_31531394_lamp1.pdf
Other Text extracted KLBFSource file signed link, expires in 15 minutes
Extracted text 5
Page 1
SIARAN PERS
PRESS RELEASE
No. 074/KFCP-DIR/PR/X/23
Kalbe Mempertahankan Pertumbuhan Penjualan yang Positif
di Sembilan Bulan Pertama 2023
Kalbe Maintained Positive Top Line Growth in the First Nine Months of 2023
Jakarta, 31 Oktober 2023 – PT Kalbe Jakarta, October 31, 2023 – PT Kalbe
Farma Tbk dan entitas anak (“Kalbe” atau Farma Tbk and Subsidiaries (“Kalbe” or
“Perseroan”) hari ini mengumumkan “the Company”) today announced that net
penjualan bersih mencapai Rp 22.561 sales reached Rp 22,561 billion in the first
miliar di sembilan bulan pertama 2023, nine months of 2023, growing by 6.5%
meningkat 6,5% dibandingkan sembilan compared to the first nine months of 2022.
bulan pertama 2022. Sementara itu, laba Meanwhile, net income reached Rp 2,065
bersih mencapai Rp 2.065 miliar di billion in the first nine months of 2023,
Sembilan bulan pertama 2023, terjadi declined by -16.9% compared to the same
penurunan -16,9% dibandingkan periode period last year due to challenging market
yang sama tahun lalu akibat kondisi pasar in post pandemic transition. Despite market
yang menantang dalam periode transisi challenges, the Company believes that the
pasca pandemi. Walaupun menghadapi healthcare industry will continue to grow in
kondisi pasar yang menantang, Perseroan the long term along with increasing health
meyakini bahwa industri kesehatan tetap awareness.
akan bertumbuh dalam jangka panjang
seiring dengan meningkatnya kesadaran
kesehatan.
Kami meyakini pemulihan makroekonomi We believe that macroeconomic recovery
tetap memberikan peluang pertumbuhan. continues to provide growth opportunities.
Seiring dengan perubahan pola belanja As consumer spending trends change post-
konsumen pasca pandemi, kami berupaya pandemic, we strive to remain adaptive and
adaptif dan berfokus pada kebutuhan focused on consumer needs, keeping in
konsumen, dengan tetap mewaspadai mind inflationary impact to purchasing
dampak inflasi terhadap daya beli power. We continued to implement
konsumen. Kami menerapkan strategi strategies to maintain growth and business
untuk menjaga pertumbuhan dan sustainability by focusing on products
keberlanjutan bisnis dengan berfokus recovery and be more aggressive on growth
pada pemulihan produk inti dan lebih driver categories such as biologic and
agresif dalam kategori produk yang oncology, preventive, and affordable
mendorong pertumbuhan seperti kategori products. We continued to manage input
biologi dan onkologi, preventif, dan produk cost pressure and inventory, portfolio
yang lebih terjangkau untuk masyarakat. management and managing operating cost
Perseroan terus memperhatikan efficiency. The Company ensures healthy
Untuk keterangan lebih lanjut: / For further information: Hal / Page
Kartika Setiabudy, Chief Financial Officer, PT Kalbe Farma Tbk 1/5
Tel: 62-21 42873688 | email: kartika.setiabudy@kalbecorp.com
Syeren Amanda, Investor Relations, PT Kalbe Farma Tbk
Tel: 62-21 42873888 | email: syeren.amanda@kalbecorp.com
Investor Relations, PT Kalbe Farma Tbk
Tel: 62-21 42873888 | email: investor.relations@kalbecorp.com
Website: www.kalbe.co.id
Page 2
SIARAN PERS
PRESS RELEASE
No. 074/KFCP-DIR/PR/X/23
pengelolaan rantai pasok dan persediaan, financial liquidity for working capital and
mengelola portofolio produk, dan menjaga expansion. The Company will continue its
efisiensi biaya operasional. Perseroan focus on innovation to provide products and
juga mempertahankan likuiditas keuangan services to meet consumers’ needs.
yang baik untuk memenuhi kebutuhan
modal kerja dan ekspansi. Perseroan terus
berfokus melakukan inovasi produk dan
layanan untuk memenuhi kebutuhan
masyarakat.
Secara berkelanjutan, Perseroan The Company continuously works to
berupaya meningkatkan akses kesehatan improve access to healthcare for the
bagi masyarakat antara lain dengan community, among others by increasing the
meningkatkan kontribusi produk dalam contribution of products in the National
program Jaminan Kesehatan Nasional, Health Insurance program, launching
meluncurkan berbagai produk kesehatan various preventive and herbal products,
preventif dan herbal, menawarkan produk offering nutritional products that are more
nutrisi yang lebih terjangkau, memperluas affordable, expanding health services
ekosistem layanan kesehatan serta ecosystem, and developing medical
pengembangan peralatan medis. Untuk devices. To expand distribution reach, the
memperluas jangkauan distribusi, Company provides B2B platform – EMOS &
Perseroan menghadirkan platform B2B – MOSTRANS through its distribution &
EMOS & MOSTRANS melalui divisi logistic divisions. The Company also
distribusi dan logistik. Perseroan juga combines product portfolio management
menggabungkan strategi pengelolaan strategies, manages the effectiveness of
portofolio produk, mengelola efektivitas sales and marketing activities, promoting
kegiatan penjualan dan pemasaran, digital transformation, and maintains
mendorong transformasi digital, serta operational cost efficiency.
mempertahankan efisiensi biaya
operasional.
Dari segi pertumbuhan dan kontribusi per In terms of growth and contribution by
Divisi, Divisi Obat Resep Perseroan Division, Prescription Drugs Division posted
membukukan peningkatan penjualan sales growth of 31.4% to Rp 5,791 billion
sebesar 31,4% menjadi Rp 5.791 miliar from Rp 4,406 billion in the first nine months
dari Rp 4.406 miliar di sembilan bulan of 2022, and accounted for 25.7% of the
pertama 2022, serta menyumbang 25,7% Company total net sales. Distribution &
dari total penjualan bersih Perseroan. Logistics Division achieved a net sales
Divisi Distribusi & Logistik meraih increase of 3.2% to Rp 8,006 billion from Rp
Untuk keterangan lebih lanjut: / For further information: Hal / Page
Kartika Setiabudy, Chief Financial Officer, PT Kalbe Farma Tbk 2/5
Tel: 62-21 42873688 | email: kartika.setiabudy@kalbecorp.com
Syeren Amanda, Investor Relations, PT Kalbe Farma Tbk
Tel: 62-21 42873888 | email: syeren.amanda@kalbecorp.com
Investor Relations, PT Kalbe Farma Tbk
Tel: 62-21 42873888 | email: investor.relations@kalbecorp.com
Website: www.kalbe.co.id
Page 3
SIARAN PERS
PRESS RELEASE
No. 074/KFCP-DIR/PR/X/23
peningkatan penjualan bersih sebesar 7,758 billion in the same period last year and
3,2% menjadi Rp8.006 miliar, dari Rp contributed 35.5% to the Company's total net
7.758 miliar di periode yang sama tahun sales. Nutritionals Division recorded net
lalu, serta menyumbang 35,5% terhadap sales at Rp 5,895 billion in the first nine
total penjualan bersih Perseroan. Divisi months of 2023, grew by 2.5% from the
Nutrisi membukukan penjualan bersih same period in the previous year's
sebesar Rp 5.895 miliar di Sembilan bulan achievement and accounted for 26.1% of
pertama 2023, mengalami pertumbuhan Kalbe's total net sales in the first nine months
sebesar 2,5% dari pencapaian di periode of 2023. In the first nine months of 2023,
yang sama tahun sebelumnya dan Consumer Health Division recorded a sales
menyumbang 26,1% dari total penjualan decrease of -12.1% to Rp 2,869 billion
bersih Kalbe di sembilan bulan pertama compared to the first nine months of 2022
2023. Pada sembilan bulan pertama 2023, with a contribution of 12.7% to the total net
terjadi penurunan pendapatan Divisi sales of the Company in the first nine months
Produk Kesehatan sebesar -12,1% of 2023, reflecting change in consumer
dibandingkan dengan sembilan bulan spending pattern to healthcare sector.
pertama tahun 2022 menjadi Rp2.869
miliar dengan kontribusi sebesar 12,7%
terhadap total penjualan bersih Perseroan
di sembilan bulan pertama 2023,
mencerminkan perubahan pola belanja
konsumen terhadap sektor produk
kesehatan.
Perseroan berhasil mempertahankan The Company continued to maintain the
pangsa pasar produk-produk Perseroan products’ market share and to monitor the
serta terus menjaga efisiensi kegiatan efficiency of operational activities to maintain
operasional untuk mempertahankan rasio the profitability ratios. Operating profit
profitabilitas. Laba usaha mencapai Rp reached Rp 2,715 billion in the first nine
2.715 miliar di sembilan bulan pertama months of 2023 with operating profit margin
2023, dengan rasio laba usaha terhadap of 12.0%. Earnings per share reached Rp
penjualan sebesar 12,0%. Laba per 44.39 in the first nine months of 2023,
saham mencapai Rp 44,39 di sembilan decreased by -16.9% compared to the same
bulan pertama 2023, turun -16,9% period last year.
dibandingkan periode yang sama tahun
sebelumnya.
Sejalan dengan perubahan pola belanja Along with the change in consumer spending
konsumen dan daya beli masyarakat, pattern and purchasing power, the Company
revised its net sales growth target into 5%-
Untuk keterangan lebih lanjut: / For further information: Hal / Page
Kartika Setiabudy, Chief Financial Officer, PT Kalbe Farma Tbk 3/5
Tel: 62-21 42873688 | email: kartika.setiabudy@kalbecorp.com
Syeren Amanda, Investor Relations, PT Kalbe Farma Tbk
Tel: 62-21 42873888 | email: syeren.amanda@kalbecorp.com
Investor Relations, PT Kalbe Farma Tbk
Tel: 62-21 42873888 | email: investor.relations@kalbecorp.com
Website: www.kalbe.co.id
Page 4
SIARAN PERS
PRESS RELEASE
No. 074/KFCP-DIR/PR/X/23
Perseroan merevisi target pertumbuhan 7%, growing above the market rate. In
penjualan bersih tahun 2023 menjadi addition, the Company projected earnings
sekitar 5%-7% dan tetap tumbuh di atas per share growth of around -15% to -12%.
pasar. Di samping itu, proyeksi Despite increasing uncertainty due to the
pertumbuhan laba bersih per saham global financial and geopolitical crisis, the
adalah sekitar -15% hingga -12%. Company is committed to maintain product
Walaupun menghadapi ketidakpastian availability and minimize the impact of rising
yang meningkat karena krisis finansial dan raw material prices by implementing pricing
geopolitik global, Perseroan berkomitmen and portfolio management strategies. The
untuk menjaga ketersediaan produk dan Company maintained a capital expenditure
meminimalkan dampak kenaikan harga maximum budget of Rp 1.0 trillion, which will
bahan baku melalui pengelolaan harga be used to expand production and
dan portofolio. Perseroan juga distribution capacity. The dividend
mempertahankan anggaran belanja modal distribution ratio is maintained at a ratio of
maksimum sebesar Rp 1,0 triliun yang 45%-55%, while taking into account the
akan digunakan untuk perluasan kapasitas availability of funds and internal funding
produksi dan distribusi. Rasio pembagian needs.
dividen dipertahankan pada rasio 45%-
55%, dengan memperhatikan
ketersediaan dana dan kebutuhan
pendanaan internal.
Optimisme Perseroan untuk tumbuh The Company's optimism for growth,
mendorong Perseroan terus konsisten encourages the Company to consistently
melakukan aktivitas riset dan pursue research and development activities
pengembangan untuk menghasilkan inovasi to produce innovation of product and
produk dan layanan. Perseroan berupaya services. The Company strives to increase
mendorong peningkatan TKDN (Tingkat local content through various initiatives to
Komponen Dalam Negeri) melalui berbagai provide products and medical devices.
inisiatif penyediaan produk obat dan alat Through the synergy of ABGC
kesehatan. Melalui sinergi ABGC (Academician, Business, Government and
(Akademisi, Business, Government dan Community), the Company continues to
Komunitas), Perseroan terus berkolaborasi collaborate to produce products and
menghasilkan produk dan layanan yang services that can be utilized by the
dapat dimanfaatkan oleh masyarakat dan community and are able to contribute to the
mampu memberikan kontribusi pada Company's business performance.
performa bisnis Perseroan.
Untuk keterangan lebih lanjut: / For further information: Hal / Page
Kartika Setiabudy, Chief Financial Officer, PT Kalbe Farma Tbk 4/5
Tel: 62-21 42873688 | email: kartika.setiabudy@kalbecorp.com
Syeren Amanda, Investor Relations, PT Kalbe Farma Tbk
Tel: 62-21 42873888 | email: syeren.amanda@kalbecorp.com
Investor Relations, PT Kalbe Farma Tbk
Tel: 62-21 42873888 | email: investor.relations@kalbecorp.com
Website: www.kalbe.co.id
Page 5
SIARAN PERS
PRESS RELEASE
No. 074/KFCP-DIR/PR/X/23
Di lain pihak, Perseroan terus membangun On the other hand, the Company continues
kerja sama dengan berbagai pihak, baik to build cooperation with various parties,
dalam bentuk perusahaan patungan, akusisi either in the form of joint-ventures,
atau bentuk kolaborasi lainnya. Perusahaan acquisitions or other forms of business
memperkuat kolaborasi riset dan uji klinis cooperation. Among such collaborations, the
dengan pihak ketiga untuk produk Company is conducting collaborative
penemuan baru (novel products) melalui PT research and clinical trials with third parties
Kalbe Genexine Biologics (KGBio), for new invention products (novel products)
melanjutkan proses integrasi PT Kalventis through PT Kalbe Genexine Biologics
Sinergi Farma untuk memperkuat Divisi (KGBio), integration of PT Kalventis Sinergi
Obat Resep serta memperkuat pasar Farma to strengthen Prescription
ekspor melalui anak perusahaan patungan Pharmaceuticals business and
seperti Global Starway Synergy Co., Ltd di strengthening export presence through
China serta Kalbe Ecossential International Global Starway Synergy Co., Ltd in China
Inc. di Filipina. and Kalbe Ecossential International Inc. In
the Philippines.
Sekilas Kalbe
PT Kalbe Farma Tbk (“Kalbe”) berdiri sejak Kalbe at a Glance
tahun 1966 dan merupakan salah satu PT Kalbe Farma Tbk. (“Kalbe”) was
perusahaan farmasi terbuka terbesar di Asia established in 1966 and is one of the largest
Tenggara. Kalbe memiliki empat divisi publicly-listed pharmaceutical companies in
utama yang menangani portofolio merek Southeast Asia. Kalbe has four main
yang handal dan beragam; Divisi Obat divisions managing a broad and strong
Resep; Divisi Produk Kesehatan yang portfolio of brands; Prescription
menangani obat bebas, juga minuman Pharmaceuticals Division, Consumer Health
suplemen dan siap saji, Divisi Nutrisi; dan Division comprising over-the-counter drugs,
Divisi Distribusi & Logistik. Kalbe kini as well as supplement drink and ready to
memiliki lebih dari 40 anak perusahaan dan drink products, Nutritionals Division, and
14 fasilitas produksi berstandar Distribution & Logistics Division. Kalbe
internasional, mempekerjakan sekitar currently has more than 40 subsidiaries and
16.000 karyawan dan mempunyai 72 14 production facilities with international
cabang distribusi & logistik di seluruh standards, employed around 16,000
Indonesia. Sejak tahun 1991, saham Kalbe employees and have 72 branches of
tercatat di Bursa Efek Indonesia (IDX:KLBF). distribution & logistics across Indonesia.
Since 1991, Kalbe’s shares have been listed
on the Indonesia Stock Exchange (IDX:
KLBF).
Untuk keterangan lebih lanjut: / For further information: Hal / Page
Kartika Setiabudy, Chief Financial Officer, PT Kalbe Farma Tbk 5/5
Tel: 62-21 42873688 | email: kartika.setiabudy@kalbecorp.com
Syeren Amanda, Investor Relations, PT Kalbe Farma Tbk
Tel: 62-21 42873888 | email: syeren.amanda@kalbecorp.com
Investor Relations, PT Kalbe Farma Tbk
Tel: 62-21 42873888 | email: investor.relations@kalbecorp.com
Website: www.kalbe.co.id
Names mentioned 0 people and organisations named in the text · linked when the evidence is strong
The name pass has not read this document yet.
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.